Dyne Therapeutics to Present at 39th Annual J.P. Morgan Healthcare Conference
January 05, 2021 07:30 ET
|
Dyne Therapeutics, Inc.
WALTHAM, Mass., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a muscle disease company focused on advancing innovative life-transforming therapeutics for people living...
Dyne Therapeutics to Present at Upcoming Investor Conferences
November 09, 2020 07:30 ET
|
Dyne Therapeutics, Inc.
WALTHAM, Mass., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a muscle disease company focused on advancing innovative life-transforming therapeutics for people living...
Dyne Therapeutics Reports Third Quarter 2020 Financial Results and Recent Highlights
November 05, 2020 07:35 ET
|
Dyne Therapeutics, Inc.
- Successful Financings, including $268 Million Initial Public Offering and $116 Million Series B Expected to Fund Through Proof of Concept Data in Co-lead Programs, Myotonic Dystrophy Type 1 and...
Dyne Therapeutics Announces Closing of Initial Public Offering
September 21, 2020 16:05 ET
|
Dyne Therapeutics, Inc.
WALTHAM, Mass., Sept. 21, 2020 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a muscle disease company focused on advancing innovative life-transforming therapeutics for patients with...
Dyne Therapeutics Announces Pricing of Initial Public Offering
September 16, 2020 19:00 ET
|
Dyne Therapeutics, Inc.
WALTHAM, Mass., Sept. 16, 2020 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a muscle disease company focused on advancing innovative life-transforming therapeutics for patients with...